Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation. GenSciP166 was assayed in vitro as ...
Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have prepared and tested proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety ...
Nurix Therapeutics secures a $15 million license extension from Sanofi for its STAT6 program, totaling $127 million to date. Nurix Therapeutics announced that Sanofi has exercised its option to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results